Please try another search
For the fiscal year ended 31 December 2017, Bioverativ Inc revenues increased 32% to $1.17B. Net income before extraordinary items decreased 32% to $296.8M. Revenues reflect Domestic segment increase of 31% to $985.1M, Japan segment increase of 31% to $138.8M, Other segment increase of 61% to $44.6M. Basic Earnings per Share excluding Extraordinary Items decreased from $4.07 to $2.75.
Period Ending: | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 |
---|---|---|---|---|
Total Revenue | 328.7 | 291.6 | 289.1 | 259.1 |
Gross Profit | 258.4 | 226.1 | 208.6 | 195.8 |
Operating Income | 117.9 | 103.8 | 113.6 | 111.9 |
Net Income | 141.3 | 67.9 | 77.1 | 69.3 |
Period Ending: | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 |
---|---|---|---|---|
Total Assets | 1618.3 | 1453.5 | 1357.5 | 796.6 |
Total Liabilities | 720.7 | 703.2 | 685.3 | 211.5 |
Total Equity | 897.6 | 750.3 | 672.2 | 585.1 |
Period Ending: | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | 590.7 | 377.6 | 241.4 | 108.2 |
Cash From Investing Activities | -408.8 | -407.3 | -406.3 | -6.3 |
Cash From Financing Activities | 253.6 | 253 | 301.9 | 256.3 |
Net Change in Cash | 436.5 | 224.1 | 137.4 | 358.7 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review